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ABSTRACT
We studied the intrahost evolution and dynamics of a multidrug-resistant HIV-1, which contains an insertion
of two amino acids (aa) and several aa changes within the reverse transcriptase (RT) gene. From an individ-
ual receiving intermittent therapy, sequences of 231 full-length molecular clones of HIV-1 RT were obtained
from serum-derived viruses at 12 consecutive time points over a period of 6 years, 17 to 20 clones per time
point. In the 3.5-year period prior to the first course of therapy, only wild-type (wt) viruses were found. As
soon as 6 months after the start of zidovudine (AZT) monotherapy, all viruses contained an insertion of two
aa between positions 68 and 69 of the RT and aa changes at positions 67 and 215, a combination conferring
resistance to multiple nucleoside analogs. After termination of therapy, the insertion mutants were rapidly
and completely replaced by the wt viruses. In turn, the insertion mutants replaced the wt viruses after initi-
ation of therapy with 3TC, d4T, and saquinavir. After termination of triple therapy, the wt viruses completely
replaced the mutants within 1 month, which is markedly faster than has been observed earlier for the re-
placement of AZT-resistant viruses. Fast replacements of the mutant virus populations after termination of
therapy indicate gross competitive disadvantage of the insertion mutant in the absence of therapy, which we
estimated by using several models. The insertion mutants attained high virus loads, demonstrating that virus
load cannot be used as a direct measure of virus fitness.
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INTRODUCTION
SEVERAL REVERSE TRANSCRIPTASE (RT) and protease inhibi-tors are now available for treatment of HIV-1 infection, with
drug combinations being more effective than monotherapy.1–5
A general problem in antiretroviral treatment is the develop-
ment of drug-resistant virus mutants.6–8 The rate of appearance
of drug-resistant mutants and their drug susceptibility profiles
are highly variable among patients and depend on multiple fac-
tors, including therapy potency, drug levels, and patient com-
pliance.
A number of mutations within the RT and protease have been
associated with resistance to antiretroviral drugs, with the list
of drug-resistant mutations being constantly extended. Until re-
cently, all described RT-resistant mutations have been amino
acid changes in the RT gene. We9 and others10,11 have identi-
fied a new type of multidrug-resistant HIV-1 mutants, which
have an insertion of two amino acids between codons 68 and
69 (or 69 and 70, depending on sequence alignment) and an
amino acid change at position 215 (T215Y), which is associ-
ated with zidovudine (AZT) resistance. In most of the mutants,
an amino acid change at position 67 (D67E, G, or S) is also ob-
served.9–16 Moreover, the insertion mutants have one or two
amino acid changes just before or after the insertion, making
sequence alignment and numbering of sequence positions in this
region ambiguous. The insertion mutants are resistant to an un-
precedentedly broad spectrum of nucleoside RT inhibitors, in-
cluding AZT, 3TC, d4T, ddI, and ddC.9–11,17,18 Site-directed
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mutagenesis experiments have confirmed the role of the inser-
tion alone, as well as in combination with the T215Y change,
in conferring reduced susceptibility to most RT nucleoside in-
hibitors.10,11,17 Genotypic analyses have revealed that the in-
sertion mutants are present in about 3% of individuals with the
T215Y change, which is one of the most common drug-resis-
tant mutations.9,10,16,18,19 So far, the appearance of the inser-
tion mutants could not be related to a certain therapy regimen,
as those mutants were derived from patients after prolonged
switching therapy.9–11,15,16,18–20 Originally, based on treatment
histories of individuals harboring the insertion mutants, it has
been suggested that the insertion mutants are specifically se-
lected by treatment regimens containing ddI or ddC alone or in
combination with AZT, but not during 1–3 years of AZT
monotherapy.10
In the present study, we analyzed the evolution of the HIV-
1 RT gene in an individual treated with various antiretroviral
drugs. We demonstrated that multidrug-resistant insertion mu-
tants do arise and may be selected during AZT monotherapy.
By analyzing virus population dynamics over a 6-year period
in relation to availability and kind of therapy, we demonstrated
substantial differences in fitness between the wild-type (wt) and
mutant viruses, dependent upon the drug environment. Our re-
sults demonstrate the capacity of the insertion mutant to main-
tain high virus loads in the presence of drugs.
MATERIALS AND METHODS
Patient history
The patient presented in this study was visiting the Acade-
mic Medical Center, Amsterdam, for follow-up and was de-
scribed in our previous study9 as patient 2. The patient was ini-
tially treated by AZT alone, with short courses of AZT therapy
in combinations with 3TC, or ddI, or RTV (Fig. 1). Since the
patient has failed on this therapy, it has been terminated. Later,
triple therapy with 3TC, d4T, and SQV was initiated. Plasma
sample obtained from the patient during triple therapy contained
high levels of HIV-1 RNA, and therefore triple therapy was ter-
minated. Phenotypic analysis of a virus isolated from the pa-
tient during triple therapy revealed high resistance to AZT, 3TC,
and d4T, and moderate resistance to ddI and ddC.9 At this time
point, the virus contained an insertion of two amino acids be-
tween codons 68 and 69 of RT, as well as amino acid changes
at codons 67 and 215. To study the evolutionary changes in
virus populations in relation to availability and type of therapy,
we sequenced full-length RT clones from viruses obtained from
plasma samples of the patient at 12 time points over a 6-year
period. The history of the treatment regimens, HIV-1 RNA
loads, CD41 cell counts, and sampling moments are shown in
Fig. 1.
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FIG. 1. HIV-1 serum RNA copy numbers (closed circles, continuous line), CD41 cell counts (open circles, dashed line), treat-
ment history, and sampling moments (triangles) for the study individual. Closed and open triangles show the presence of the wt
virus and the insertion mutant, respectively.
RNA isolation, amplification, and cloning
RNA was isolated from 200 ml of serum. HIV-1 RNA copy
numbers were determined in all samples (NucliSens assay,
Organon Teknika, Boxtel, The Netherlands). cDNA was ob-
tained in an RT reaction by using the antisense primer 39-RT-
OUT (59-CTACTTGTCCATGCATGGCTTCT, HxB2 posi-
tions 4391–4369). A fragment of 1906 nucleotides
encompassing the whole RT gene was amplified by using the
sense primer 59-P66-OUT (59-ACCTACACCTGTCAA-
CATAAT, 2485–2505) and the antisense primer 39-RT-OUT.
The Taq polymerase (Boehringer Mannheim, Mannheim, Ger-
many) was used for all amplification reactions.
A nested PCR was performed with primers 59-ET27 (59-
GACTCAGATTGGTTGCACTTTAAATTTTCC, 2521–2550)
and 39-RT22 (59-AGGTTAAAATCACTAGCCATTGC-
TCTCC, 4284–4311). One microliter of the product (, 20
ng/ml) was ligated into the pCR 2.1-TOPO vector (Invitrogen,
San Diego, CA) according to the manufacturer’s instructions.
Two microliters of the cloning reactions was transfected into
TOP10 cells (Invitrogen, San Diego, CA).
From each plate, 30 colonies were picked up and tested for
an insert with a PCR using primer set II: 59-SP6-C-seq (59-
GATTTAGGTGACACTATAGGGTATACTGCATTTAC-
CATACC, 2926–2946) and 39-T7-D-seq (59-TAATACGACT-
C A C T AT A G G G G C T A G CT G C C C C A TC T A C A T A ,
3889–3869). The products from positive clones (called frag-
ment II) were used for sequencing.
For each positive clone, two other fragments, I and III, were
generated with nested PCR by using primers 59-ET27 (59-
CAGTCAGATTGGTTGCACTTTAAATTTTCC, 2521–2550)
and 39-END-PROT-T7 (59-TAATACGACTCACTATAGGG -
GGAATATTGCTGGTGATCCTTTCCA, 3029–3005), for
fragment I, and 59-SP6-D-SEQ (59-GATTTAGGTGACAC -
TATAGGGGGAAAATTGGAATTGGGCAA, 3331–3350)
and 39-E-seq-T7 (59-TAATACGACTCACTATAGGG TGCT-
CTCCAATTACTGTGAT, 4291–4272), for fragment III.
Sequencing and sequence analysis
For each of the 12 serum samples (Fig. 1), 17–20 full-length
RT clones were sequenced. For each clone, three overlapping
PCR fragments were sequenced. The final sequences were 1680
nucleotides in length. The PCR fragments were sequenced from
the noncoding strand for fragments I and III with the T7 primer
(59-TAATACGACTCACTATAGGG ), and from the coding
strand for fragment II with the SP6 primer (59-GATTTAGGT-
GACACTATAGG) by using the ABI Prism BigDye termina-
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TABLE 1. SEQUENCE CHARACTERISTICS OF HIV-1 RT CLONES AT AMINO ACID POSITIONS
66–71 AND 215 AT EACH TIME POINT IN RELATION TO THERAPY EVENTS
Sequence characteristics of the RT clones
Time points Therapy event Number of clones Positions 66–71 Number of clones Position 215
HIV B consensus K D S . . T K Wa T
1 and 2 Before therapy 38/38 - - - . . - - - 38/38 –
3 162 days of AZT 10/19 - N - S S G A - 19/19 Y
monotherapy 5/19 - S - S S G A -
3/19 - T - S S G A -
1/19 - N - S S G T -
4 208 days of AZT, 19/20 - S - S S G A - 20/20 Y
20 days of 3TC 1/20 - T - S S G A -
5 146 days of the 20/20 - S - S S G A - 20/20 Y
second AZT course,
26 days of RTV
6 133 days after 20/20 - - - . . - - - 20/20 –
termination of AZT
7 First day of 3TC, 20/20 - - - . . - - - 20/20 –
d4T, and SQV
8 28 days of 3TC, 9/19 - S - S S G T - 19/19 Y
d4T, and SQV 8/19 - S - S S G A -
1/19 - S - S S D T -
1/19 - S - G S D T -
9 55 days of 3TC, 18/19 - S - S S G T - 19/19 Y
d4T, and SQV 1/19 - S - S R G T -
10 126 days of 3TC, 18/19 - S - S S G T - 19/19 Y
d4T, and SQV 1/19 - N - S S G A -
11 21 days after 20/20 - S - S S G T - 20/20 Y
termination of
3TC, d4T, and SQV
12 62 days after 17/17 - - - . . - - - 17/17 –
3TC, d4T, and SQV
aIn the sequence alignment, dashes indicate amino acid identity with the consensus, and dots indicate the absence of aa at this 
position. 
tor cycle sequencing kit. The sequence products were analyzed
on an automatic sequencer (ABI Prism DNA sequencer model
377XL).
The sequences were aligned manually. Phylogenetic analy-
sis was performed by using MEGA software (neighbor-joining
method), based on nucleotide distances calculated according to
the Kimura two-parameter distance estimation method as well
as synonymous distances.21,22 The sequences are deposited in
the GenBank, accession numbers AF331192–AF331422. To
characterize intrasample sequence heterogeneity, time point
consensus sequences were calculated as the mean of all clones
obtained at this time point, and the Kimura two-parameter dis-
tances of all individual sequences to the time point consensus
were calculated. Statistical comparison of intrasample hetero-
geneity was performed by using the t test.
RESULTS
Virus evolution and dynamics of virus populations in
relation to therapy
To study the evolution of HIV-1 populations in relation to
availability and type of therapy, 231 full-length RT clones (1680
nucleotides in length) were sequenced from viruses obtained at
12 time points over a 6-year period, 17–20 clones per time point.
During the observation period, the individual received AZT
alone or in combination with 3TC, or ddI, or RTV, triple ther-
apy by 3TC, d4T, and SQV, or no antiretroviral therapy. The
treatment history and sampling moments are shown (Fig. 1).
Numbers of clones sequenced at each time point and sequence
heterogeneity observed among clones at amino acid positions
66–71 and 215 are shown (Table 1). The consensus sequences
of virus populations that became selected during each treatment
regimen as well as in the absence of therapy are shown (Fig.
2).
The amino acid sequences of RT clones obtained from the
individual at two time points before the first course of AZT
monotherapy contained no insertions and were identical to the
subtype B consensus in this region (66-KDSTKW-71, Fig. 2
and Table 1). All clones had a Thr at position 215, which is
also characteristic of wt virus.
As soon as 162 days after the start of AZT monotherapy
(time point 3), all obtained viruses contained an insertion of
two amino acids between codons 68 and 69, amino acid changes
at positions 67, 69, and 70, as well as an amino acid change
T215Y (Table 1). Sequence heterogeneity was observed at po-
sition 67: the wt codon GAC (D) was changed into AAC (N,
11/19 clones; one nucleotide substitution), ACC, or AGC (T,
3/19 clones, or S, 5/19 clones, respectively; both changes re-
quire two nucleotide substitutions). All but two (115/117) of
the insertion mutants obtained later in infection had S at this
position, suggesting a selection for this amino acid. Therefore,
sequence heterogeneity observed at position 67 at time point 3
is likely a reflection of the following evolutionary pathway:
GACR AACR AGC.
Since, besides the insertion, there were amino acid changes
at positions 69 and 70 (Table 1), the evolutionary pathway of
these sequence changes could not be reconstructed. These
changes could be a result of an SS insertion between codons
68 and 69 and amino acid changes at positions 69 and 70 (TKR
GA), or of amino acid changes TKR SS at these positions with
an insertion of GA after position 70, or more complex evolu-
tionary processes (e.g., deletion of TK, insertion of SSGA). Be-
sides the insertion and amino acid changes at positions 67 and
215, there were two other amino acid differences between the
consensus sequences of the wt and mutant populations—L329I
and R350K (Fig. 2). At both of these positions, the consensus
sequences of the insertion mutants were identical to the sub-
type B consensus (Fig. 2). Moreover, at both of these positions
extensive sequence variation was observed among the wt as
well as mutant populations during the observation period (not
shown). Therefore, these differences between the wt and mu-
tant consensus sequences are unlikely to be related to the drug-
resistant phenotype or to reflect compensatory changes. Rather,
they could be a result of sampling effects. A number of other
amino acid changes was observed in individual sequences
among both the wt and mutant population, reflecting the high
mutation rate of HIV-1 (Fig. 3). The means and ranges of in-
trasample sequence distances found in our study were similar
to the levels of virus heterogeneity that are generally observed
in infected patients.23
The insertion mutants were the only viruses found in the in-
dividual during ongoing therapy by AZT alone (Fig. 1, time
point 3) or in combination with 3TC (time point 4) or RTV
(time point 5). The mutant virus population in serum was com-
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FIG. 2. Consensus sequences of the RT gene of HIV-1 populations that were selected at the end of each treatment regimen as
well as in the absence of antiretroviral therapy. For each time point, consensus sequences were calculated as the arithmetic mean
of all individual clones obtained at this time point. The HIV-1 subtype B consensus is shown for comparison. Dashes indicate
amino acid identity with the subtype B consensus; dots are introduced to facilitate alignment. Amino acid positions are num-
bered starting from the first amino acid of the RT protein.
pletely replaced by the wt viruses 133 days after the termina-
tion of therapy (time point 6). Wt viruses were present in serum
until the beginning of triple therapy (time point 7, Table 1 and
Fig. 2).
As early as 28 days after the initiation of triple therapy by
d4T, 3TC, and SQV, the wt virus population was completely
replaced by the mutant population (time point 8, Table 1). At
this time point, sequence heterogeneity within the region of
insertion was found among clones. The virus variant contain-
ing an SSGA insertion, which was the major insertion variant
in earlier samples (time points 3–5, 58/59 clones), was found
in only 8 of 19 clones sequenced at time point 8 (Table 1).
Previously unseen virus variant, containing an SSGT inser-
tion and an D67S amino acid change, was found in 9 of 19
clones. An A to T amino acid change within the insertion was
caused by a single nucleotide substitution (GCAR ACA).
Two other clones contained insertions of SSDT or GSDT,
which have not been found earlier or later in infection 
(Table 1).
The SSGT variant, which was still in the minority at time
point 8 (9/19 clones), was subsequently selected for. It was the
major variant 55 and 126 days after the initiation of triple ther-
apy (time points 9 and 10, 18/19 clones at both time points)
and was the only variant observed in the first sample after the
termination of triple therapy (time point 11, 20/20 clones).
Sixty-two days after the termination of triple therapy, the in-
sertion mutant population was replaced by the wt viruses (Table
1 and Fig. 2, time point 12).
Virus population heterogeneity
To characterize the intrasample heterogeneity of virus pop-
ulations, we calculated genetic distances of sequences obtained
at each time point to the respective time point consensus (Fig.
3). At all time points (except for time point 1), the mean het-
erogeneity of the wt virus populations was higher than that of
the mutant populations. After the initial (between time points
1 and 2) increase, genetic heterogeneity of the wt viruses sta-
bilized. In contrast, the intrasample heterogeneity was decreas-
ing during both periods when the insertion mutants were found
in the individual (Fig. 3, time points 3–5 and 8–11). During
AZT therapy, a decreasing intrasample sequence heterogeneity
coincided with the addition of new drugs to the treatment reg-
imen (after the start of 3TC therapy, time point 4, and after the
start of RTV therapy, time point 5). During the reappearance
of the insertion mutants, their intrasample heterogeneity was
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FIG. 3. Intrasample nucleotide sequence heterogeneity of HIV-1 populations at each time point. For each time point, a con-
sensus sequence was calculated as the mean of all clones present at this time point. Circles show genetic distances of each clone
to the time point consensus; horizontal lines show the mean distances. Closed and open circles show the presence of the wt virus
and the insertion mutant, respectively. p-Values for the comparisons of genetic distances and time intervals between consecutive
time points are shown. Therapy periods are boxed.
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FIG. 4. Phylogenetic analysis of virus RT sequences obtained from the study individual, based on the Kimura two parameter
distances (A) and synonymous distances (B). Since the trees that include all sequences are too large to be presented, phyloge-
netic analysis of selected sequences is shown. Similar results were obtained when all sequences were included in the analysis.
Sequences are labeled by their sampling moments (T??) and clone numbers (C??). The insertion mutants are marked by an as-
terisk (*). Bootstrap values for the insertion mutant cluster are shown (100 replications). For (A), sequences from participants
of the Amsterdam cohort of homosexual men are included as local controls. For (B), the subtype B consensus sequence is used
to root the tree.
B
relatively stable during triple therapy and decreased markedly
after its termination (Fig. 3, time point 10).
Phylogenetic relationships between the insertion
mutants and the wt viruses
Phylogenetic analysis based on nucleotide distances revealed
separation of virus clones into two clusters according to pres-
ence or absence of the insertion (Fig. 4A). Yet, the wt and mu-
tant sequences clustered together and separately from local con-
trols (sequences from participants of the Amsterdam cohort
studies of homosexual men, Fig. 4A). This observation strongly
suggests that the appearance of the insertion mutants is the re-
sult of the intrahost evolution of the original wt virus popula-
tion, and not that of superinfection. Moreover, insertion mu-
tants present in the individual during triple therapy (time points
8–11) were phylogenetically closely related to the early virus
mutant population (time points 3–5). To additionally support
this observation, we analyzed synonymous differences among
virus sequences21,22 (Fig. 4B). Since synonymous substitutions
do not change amino acids (and, therefore, virus phenotype),
their analysis could not be biased by convergent evolution un-
der selective pressure of antiretroviral drugs (when, for instance,
a T215 amino acid change arises independently in two differ-
ent virus populations, artificially making them more similar in
a phylogenetic analysis). Our analysis of synonymous distances
resulted in the bootstrap value for the mutant sequence cluster
dropping from 96 to 10 (Fig. 4A versus 4B). Moreover, early
(time points 3–5) and late (time points 8–11) insertion mutants
did not form separate clusters (Fig. 4B). This finding is evi-
dence for the reappearance of the insertion mutants being re-
lated to an expansion of the original mutant (still present in
long-lived cells and/or body compartments other than serum)
rather than to a new insertion. Our observation that each time
the wt or mutant virus populations reappeared in the individ-
ual, they were heterogeneous (Fig. 3, time points 6, 8, and 12),
suggests that their reservoirs are extensive.
Relative fitness of the insertion mutant
The fast replacement of the wt virus by the insertion mutant
during therapy and the fast reversion to the wt after termina-
tion of therapy (Table 1 and Fig. 1) suggest substantial fitness
differences. We developed two models to estimate the relative
fitness of the insertion mutant from the virus dynamics. Since
the insertion in the RT is expected to influence the replication
rate of the virus, but not its half life, we write
}
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M
t
} 5 r(11 s)M2 dM (1)
for the dynamics of wt virus W and mutant virus M. The r is
the (wt) replication rate, 1/d is the generation time, and s is the
classical coefficient of selection. Because this model combines
the dynamics of productively infected cells and free virions, the
generation time should be about 2 days.24,25 The same model
was used before for estimating selection coefficients.26,27
For estimating the relative fitness (11 s), write the solutions
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and time t:
s 5 }
r
1
t
} 1 ln }MW
(
(
t
t
)
)
}2 ln }
M
W
(
(
0
0
)
)
} 2 (2)
p 5M/(W 1 M) may be defined as the frequency of the mu-
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Thus, for estimating the relative fitness, we need to know the
ratio of the genotype frequencies and the total replication rt.27
Both are not provided by the data however.
First consider the reversion to wt virus between time points
11 and 12, i.e., 21 and 62 days after termination of triple ther-
apy. At time point 11, 20/20 sequences were mutants, and 41
days later 17/17 sequences were wt. Since 1 2 p 5 0 and p 5
0 at time points 11 and 12, respectively, we cannot employ Eq.
(3). Additionally, not knowing the true frequencies of wt virus,
we cannot estimate its replication rate r. Similar problems ap-
ply to the data during treatment. At time points 7 and 8, 20/20
sequences were wt and 19/19 sequences had the insertion, re-
spectively.
Previous publications estimated that the doubling time of wt
HIV-1 following therapy interruption is about 1.6 days28 to 2.0
days.29 In terms of Eq. (1), an average of 1.8 days means that
r 2 d 5 ln 2/1.8 < 0.4/day. Knowing that d < 0.5,24,25 we es-
timate that between time points 11 and 12 r 5 0.9/day. Con-
sidering a “worst case scenario” for the genotype frequencies
by assuming that the next sequence to be sampled would be of
the other type, a conservative estimate of the ratio (M/W [or
p/(12 p)] at time points 11 and 12 is 20 and 1/17, respectively.
The corresponding s becomes
s 5}
ln(1
0
/
.
1
9
7
3
) 2
41
ln20
} 520.16 (4)
Thus, the relative fitness of the insertion mutant should be
less than 84%, compared to the wt virus. Since the replication
rate r during treatment is not known, it is not possible to use a
similar approach for time points 7 and 8.
In the Appendix, we resolve these problems by developing
a model for calculating the likelihood of any combination of
fitness difference r and initial frequency p(0). This gives a min-
imal estimate for the s. We compute the smallest selection co-
efficient that is obtained with 95% probability. The Appendix
develops from the model given in Eq. (1) by changing the in-
terpretation of W being the loser and M being the winner. The
selection coefficient should therefore be positive. We estimated
an upper bound for the replication rate r of the loser by the ex-
pansion of the total virus load. Between time points 11 and 12,
the total virus load expands 2.36-fold in 41 days, and between
time points 7 and 8, the virus load expands 2.56-fold in 27 days.
Solving ln 2.36 5 (r 2 d) 3 41 and ln 2.56 5 (r 2 d) 3 27
with d 5 0.5/day,25 we obtain r 5 0.52/day for the replication
rate of the mutant in the absence of therapy, and r 5 0.53/day
for the replication rate of the wild-type virus during therapy.
Note that the upper bound r 5 0.52/day estimate for the repli-
cation rate of the insertion mutant in the absence of therapy is
nevertheless smaller than the r(12 s) 5 0.9 3 0.84 5 0.76/day
estimate used above, meaning that the true doubling time dur-
ing this interval is longer than 1.6 days.
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Figure 5 depicts a contour plot of the likelihood that the data
are explained by any combination of the fitness difference rs
[see Eq. (1)] and p(0) (i.e., the initial frequency of the winner).
From Fig. 5A, where the mutant is the winner between time
points 7 and 8, we read that the minimal value on the 95% lower
confidence level is rs < 0.185, which is attained around an ini-
tial frequency of the insertion mutant of p(0) 5 0.075. Because
we estimated r # 0.53/day for the replication rate of the wt virus
during therapy, we estimate s $ 0.35. The relative fitness of the
insertion mutant during treatment should therefore be 135% at
least.
From Fig. 5B, in which the wt is the winner between time
points 11 and 12, we read a minimal value of rs < 0.12 at the
95% confidence limit, which is attained around an initial fre-
quency of the wt virus of p(0) < 0.072. Because we estimated
r # 0.52/day for the replication rate of the mutant in the ab-
sence of therapy, we estimated s . 0.23. The relative fitness of
the insertion mutant in the absence of therapy should therefore
be less than 100/1.23 5 81%, close to the fitness of 84% esti-
mated above.
DISCUSSION
Recently, several groups have reported a new type of drug-
resistant HIV-1 mutants, which have an insertion of two amino
acids between codons 68 and 69 in combination with amino
acid changes at position 215 and, in most cases, at position
67.9–11,13,20 Frequencies of the insertion mutants in treated pop-
ulations were remarkably consistent in several studies: about
3% of individuals with the T215Y change.9,10,18,19 So far, the
appearance of the insertion mutants could not be related directly
to particular therapy regimens,9,13,15,20 although it has been sug-
gested that selection by ddI and/or ddC, and not by AZT
monotherapy, is likely to play a role.10
In the present study, we established that multidrug-resistant
insertion mutants do arise and can be selected for by AZT
monotherapy. In addition to previous studies, in which exten-
sive genetic variation of the insertion mutants among individ-
uals (interhost heterogeneity) has been noted, we provide data
on the intrahost evolution of this mutant. Generation of a so
complex mutant requires multiple evolutionary events, which
we were able to trace in our study. Previously, three sequence
patterns have been found in insertion mutants: (1) an insertion
of two amino acids between codons 68 and 69 together with
amino acid changes at adjacent positions, (2) a T215Y change,
and (3) amino acid changes at position 67 (in the majority of
mutants). In our study, the earliest observed insertion mutant
(at time point 3) already had all three sequence changes. While
the T215Y amino acid change was conserved in all insertion
clones over time, we observed the evolution of the other two
sequence patterns. As the result of a single nucleotide substi-
tution, the wt D at position 67 was changed into N in the ma-
jority of early insertion mutants (Table 1). A second nucleotide
substitution within the same codon resulted in the second amino
acid change (DR NR S), which was rapidly selected for.
Based on these data, we suggest that the D67N mutant is less
fit and represents an intermediate variant during the 67D to 67S
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FIG. 5. The likelihood l as a function of the fitness difference rs and the initial frequency p(0) of the winning variant. (A) The
expansion of the insertion mutant during therapy between time points 7 and 8; p(0) is the unobserved initial frequency of the
mutant virus. (B) The expansion of the wild-type virus after therapy between time points 11 and 12; p(0) is the unobserved ini-
tial frequency of the wt virus. Shaded contours (from light to dark) depict l 5 0.5, 0.25, 0.05, and 0.01. The 95% confidence
limit for each pair [rs, p(0)] corresponds to the contour line at l 5 0.05 (see the Appendix).
evolution. Within the insertion region, the SSGA mutant, which
was present during the first therapy regimens (AZT alone or in
combination with 3TC or RTV), was also found to be one of
the two major virus subpopulations after a month of triple ther-
apy (time point 8; Table 1). Subsequently, the second major
subpopulation, containing SSGT, was selected for, suggesting
its competitive advantage.
Our observation that the earliest insertion mutant (time point
3) already had all three sequence patterns that have previously
been described in patients after years of antiretroviral therapy
suggests that these changes may be cooperative and essential for
maintaining the RT function. In the 3D structure of the RT pro-
tein, position 215 is located close to the insertion region.30,31
During both periods when the insertion mutants were present
in the individual (Fig. 3), a decreasing intrasample virus hetero-
geneity was observed. This trend was especially prominent dur-
ing the first period. It is likely that addition of 3TC and RTV to
the treatment regimen during this period resulted in population
bottlenecks.32 Successive selection of particular viruses from a
variety of insertion mutants (competitive exclusion, Table 1) may
have also contributed to a decrease of virus heterogeneity be-
tween time points 3 and 5. This phenomenon was also observed
in the second period (time points 8–11), when suppression of the
wt virus by triple therapy originally (time points 8–10) resulted
in reemergence of various competing insertion mutants. Of them,
only one variant was finally selected (time point 11, Table 1).
The observation that this variant (with an SSGT insertion), al-
though being found at earlier time points, became the only virus
variant present after termination of triple therapy may indicate
its higher fitness relative to other insertion mutants. Our finding
that the intrasample heterogeneity was higher for the wt popula-
tion than for the mutant emphasizes the importance of selection
pressure by drugs and possible benefits of therapy even if it is
not achieving maximal virus suppression.
Termination of antiretroviral therapy in patients with drug-
resistant mutants generally leads to the restoration of the wt
virus population, which is interpreted as a consequence of com-
petitive disadvantages of drug-resistant mutants in the absence
of drugs. Impaired fitness has earlier been demonstrated in cell
cultures for various drug-resistant mutants.33–39 We demon-
strated a gross competitive disadvantage of the insertion mu-
tant compared to the wt virus in the absence of drug pressure.
This conclusion is based on our observation that after termina-
tion of triple therapy, the mutant population was replaced by
the wt viruses within a month. Since in vivo fitness estimates
for viruses resistant to single RT inhibitors are not available
(except for the 215 mutants26,40), we cannot directly compare
our fitness data with those for other drug-resistant viruses. Ear-
lier, for AZT-resistant mutants, dynamics of restoration of the
wt virus population after the termination of AZT monotherapy
was described.41–43 Considering the fact that it takes from half
a year to several years for the wt viruses to replace AZT-resis-
tant mutants, and that the restoration of the wt genotype is gen-
erally incomplete,42 we suggest that the fitness decrease of
AZT-resistant mutants is less than that of the multidrug-resis-
tant insertion mutants. For an AZT-resistant, 215Y mutant, the
fitness reduction in the absence of drugs has been estimated to
be between 10% and 25%,26,40 compared to the fitness loss of
at least 16% for the insertion mutant, demonstrated in the pres-
ent study.
The HIV-1 RNA load in plasma hardly changed when, fol-
lowing termination of triple therapy, the mutant population was
replaced by the wt viruses (Fig. 1). This may seem surprising,
since lower fitness of a virus strain, which results in the pref-
erential elimination of this virus in competition with another
strain, therefore cannot be equated to lower steady-state virus
load. Besides virus fitness, other factors shaping intrahost en-
vironment, including characteristics of the immune response,
target cell availability, virus tropism, and the presence or ab-
sence of competitor viruses, may all be crucial for maintenance
of steady-state virus load.44 Therefore, it seems to be incorrect
to directly compare fitness of two HIV-1 strains based on their
loads in the host(s) without considering peculiarities and dy-
namics of the intrahost environment.
APPENDIX
The sampled sequences at time points 7, 8, 11, and 12 con-
tained either the wt viruses or the insertion mutants only. It is
therefore impossible to calculate the conventional ratios of
genotype frequencies. It is possible, however, to compute a
lower confidence limit on the fitness difference rs and to ob-
tain an upper bound estimate for the replication rate r. It will
be convenient to relabel Eq. (1) such that we always consider
the outgrowth of a “winner” that was initially present at an un-
known minority frequency p(0). Thus, the growth rate of the
winner is [r(11s) 2 d]/day, and that of the loser is (r 2 d)/day.
Since the loser completely disappears over the observation in-
terval, an upper bound of the loser’s growth rate can be ob-
tained from the expansion of the total viral load over the inter-
val. In the text, we thus estimated for the replication rate of the
wt virus between time points 7 and 8 that r , 0.52/day, whereas
that of the mutant between time points 11 and 12 should be r ,
0.53/day.
As a function of the initial frequency p(0) and the replica-
tion rate r, the frequency p(t) of the winner at the end of an ob-
servation interval of t days is given26 by
p(t) 5}
1 2 p(
p
0
(
)
0)
1
ers
p
t
(0)erst
} (5)
The absence of the minority species in all samples allows the
confidence level for any pair of parameters [rs, p(0)] to be es-
timated by computing the likelihood l of the data by the bino-
mial statistics
l 5 [12 p(0)]n(0)p(t)n(t) (6)
where n(t) is the number of sequences samples at time t, and
p(t) is provided by Eq. (5). The confidence limits then corre-
spond to contour lines at level 1 2 l [rs, p(0)]. The likelihood
l [rs, p(0)] is plotted as a gray-scale coded contour plot in 
Fig. 5.
By our simplified notation, it may seem that we have as-
sumed exponential growth over both observation intervals. A
recent paper,27 however, demonstrated that the parameter r may
be replaced by an arbitrary function r(t), allowing for nonex-
ponential growth. That study showed that r(t) can be estimated
by the total viral expansion over the observation interval. Since
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we used the same expansion to compute the replication rate r,
identical results would be obtained if the growth were nonex-
ponential.
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